Introduction
The retrovirus HTLV-I is the causative agent of adult T-cell leukemia/lymphoma (ATL), an aggressive malignancy of CD4 þ T lymphocytes (reviewed in Bazarbachi and Hermine, 2001) . Leukemia is preceded by oligoclonal expansions of HTLV-I-infected activated T cells (Wattel et al., 1995) as a result of the viral transactivator protein Tax expression, which activates various cellular genes including CREB/ATF, AP-1 and NF-kB (Sun et al., 2000) , functionally inactivates p53 and interferes with several cell cycle regulators including cyclins and cdk-inhibitors (reviewed in Yoshida, 2001) .
ATL is resistant to chemotherapy and carries a very poor prognosis (reviewed in Bazarbachi and Hermine, 2001 ). High response rates were achieved with the combination of zidovudine and interferon-a (IFN) (Gill et al., 1995; Hermine et al., 1995; Bazarbachi and Hermine, 1996) . However, most patients eventually relapse (Hermine et al., 2002) , which underlines the need for new therapeutic approaches. Arsenic trioxide (As) synergizes with IFN to induce G1 arrest and apoptosis in ATL (Bazarbachi et al., 1999) through shut-off of the NF-kB pathway and Tax degradation by the proteasome (El-Sabban et al., 2000; Nasr et al., 2003) .
PS-341 is a selective inhibitor of the 26S proteasome, a critical nuclear and cytoplasmic proteolytic system that regulates cell proliferation, differentiation and apoptosis (reviewed in Adams, 2003) . This ubiquitinproteasome pathway normally eliminates intracellular damaged, mutant and misfolded proteins and a variety of short-lived functional proteins such as cyclins and cyclin-dependent kinase inhibitors, NF-kB inhibitors and p53 (Jentsch and Schlenker, 1995; Adams, 2003) . In unstimulated cells, NF-kB is inactive, complexed in the cytosol with inhibitory subunits known as IkB. When IkB kinase complexes phosphorylate IkB proteins, they are ubiquitinated and degraded by the 26S proteasome (reviewed in Ghosh and Karin, 2002) . Consequently, free NF-kB proteins translocate to the nucleus, bind specific promoters and activate gene transcription.
PS-341 has demonstrated clinical effect in hematological malignancies (Gatto et al., 2003; Hideshima et al., 2003; Pham et al., 2003) and solid tumors (Adams et al., 1999; Ling et al., 2003) . Although PS-341 antitumor activity correlates with suppression of NF-kB activity , it also affects many intracellular regulatory molecules such as p53, p21 and p27 Hideshima et al., 2003) , blocks the antiapoptotic effects of bcl-2 and sensitizes murine myeloid leukemia cells to TRAIL-mediated apoptosis (Sayers et al., 2003) . PS-341 also blocks the cell cycle at G 2 -M phase (Adams et al., 1999; Ling et al., 2003) . In a murine model of ATL, PS-341 synergized with humanized anti-Tac monoclonal antibodies and at high doses (1 mM) decreased NF-kB DNA binding activity by preventing degradation of IkB-a (Tan and Waldmann, 2002) .
In this report, we have studied the effect of clinically achievable concentrations of PS-341 and its combination with doxorubicin or etoposide on cell growth and apoptosis of fresh ATL cells, HTLV-I transformed and HTLV-I-negative malignant T cells. Our data demonstrate selective effects on malignant cells and support a potential therapeutic role for PS-341, either alone or in combination with chemotherapy, in patients with ATL and other HTLV-I-negative T-cell lymphomas.
Results

PS-341 induces growth arrest of malignant T cells
We used four HTLV-I-transformed cell lines (HuT-102, MT2, C8166 and C91PL) and four HTLV-I-negative T-cell lines (CEM, . Achievable plasma concentrations of PS-341 ranging from 3 to 10 nM resulted in a dose-and time-dependent growth inhibition of all malignant T cells (Figure 1) , while treatment at 1 nM had no significant effect. In general, HTLV-I-negative cells were more sensitive to PS-341 than HTLV-I transformed cells (Po0.01; Dunnett test). Complete growth inhibition was observed at 24 h post-treatment in three HTLV-Inegative cell lines CEM, Molt-4 and HuT-78 at PS-341 concentrations of 3-5 nM, while Jurkat cells required 48 h treatment at 10 nM for maximal growth inhibition. In HTLV-I infected cells, MT-2 cells were most sensitive with complete growth inhibition by PS-341 treatment at 5 nM for 24 h while HuT-102, C8166 and C-91PL cell lines required treatment at 10 nM concentration for 48-72 h to achieve complete growth inhibition. Significantly, PS-341 almost completely inhibited the growth of resting or PHA-stimulated freshly isolated ATL cells by 48 h at 5 and 10 nM. By contrast, normal T cells from two healthy donors were completely resistant to PS-341 treatment up to 10 nM (Figure 1 and data not shown). Effect of PS-341 on HTLV-I transformed and negative T cells R Nasr et al
PS-341 treatment induces apoptosis in malignant T cells
Using TUNEL assay we investigated the involvement of apoptosis in PS-341-induced growth inhibition of HTLV-I-positive and -negative malignant T-cells. After 48 h of culture, the percentage of TUNEL-positive HuT-102 cells reached 25% with 10 nM PS-341 while CEM cells were more sensitive to PS-341-induced apoptosis reaching 92% TUNEL-positive cells with 5 nM PS-341 (Figure 2a) . Similarly, under fluorescence microscopy, PS-341 treatment resulted in a significant increase in the number of TUNEL-positive apoptotic MT-2 and CEM cells (Figure 2b and data not shown). PS-341-induced apoptosis was also associated with a dose-dependent dissipation of mitochondrial membrane potential as shown by the decrease in Rhodamine-123 fluorescence. This effect was evident in all tested ATLderived and HTLV-I-negative cells (Po0.01; Dunnett test) ( Figure 2c ). As expected, the dissipation of mitochondrial membrane potential correlated with sensitivity to PS-341 with a more moderate decrease observed in HTLV-I-positive cells.
PS-341 treatment causes cell cycle arrest in malignant T cells
Cell cycle analyses of all tested cell lines showed that PS-341 induced a significant dose-dependent increase in the pre-G 0 /G 1 region, regarded as apoptotic cells (Po0.01; Dunnett test). This increase was more significant in HTLV-I-negative cells in agreement with their higher sensitivity to PS-341 as compared to HTLV-I-positive cells (data not shown).
PS-341 treatment also induced significant changes in the cell cycle distribution. Figure 3 represents the relative distribution of nonapoptotic cells between G 0 / G 1 phases (black boxes) and cycling cells, the sum of (S þ G 2 /M) phases (white boxes). In HTLV-I-negative cells treated for 24 h, cycling CEM cells significantly increased from 40% in the control cells to 61 and 64% with 3 and 5 nM PS-341 respectively (Po0.01). Similar results were observed with Molt-4 cells (Figure 3 and data not shown), suggesting that PS-341 treatment induces a G 2 /M cell cycle arrest, as reported for other cell types (Adams et al., 1999; Ling et al., 2003) . Interestingly, PS-341 treatment resulted in a completely different pattern of changes in the cell cycle distribution of HTLV-I-positive cells. Indeed, after 24 h treatment, cycling HuT-102 and C91-PL cells diminished from 37 and 47% respectively in the control cells to 29 and 36%, respectively, with 3 nM PS-341 and to 26 and 34% respectively with 5 nM PS-341, while treatment with 10 nM PS-341 resulted in a secondary increase of cycling cells to 33 and 47% respectively (Figure 3 ). The same distribution was maintained in HuT-102 cells after 48 h. Similar results were also observed in C8166 cells while MT-2 cells showed a decrease in cycling cells from 50 to 47% with 3 nM PS-341 and a secondary increase to 54 and 56% with 5 and 10 nM PS-341, respectively, again in agreement with their higher sensitivity to PS-341 as compared to other HTLV-I-positive cells (data not shown). These results suggest that PS-341 treatment results in a moderate G 0 /G 1 arrest of HTLV-I-positive cells at concentrations insufficient to inhibit growth followed by a G 2 /M arrest at the growth inhibitory concentrations (10 nM for HuT-102, C-91PL and C8166; 5 and 10 nM for MT-2). (Alam et al., 1999; Olson et al., 2003) . Hence, the protective effect of zVAD demonstrates the involvement of caspase activation and caspase-dependent apoptosis in PS-341-induced growth inhibition of HTLV-I-negative cells but not ATL-derived cells.
PS-
PS-341 treatment downregulates the expression of the anti-apoptotic protein XIAP in HTLV-I-negative cells only
Tax has been reported to prevent apoptosis and caspase activation (Kawakami et al., 1999) through upregulation of the NF-kB-dependent XIAP (X-linked inhibitor of apoptosis), c-IAP-1 (inhibitor of apoptosis-1) and bcl-X L proteins. PS-341 treatment of HTLV-I-positive cells resulted in a delayed increase of bax at 48 h with 10 nM PS-341 and a minimal decrease in bcl-X L and c-IAP-1 in some tested cell lines, whereas XIAP and bcl-2 protein levels were unaffected ( Figure 5a and data not shown). In HTLV-I-negative malignant T cells, PS-341 treatment had no significant effect on bcl-2 protein level, increased bax in CEM cells but dramatically downregulated the protein level of XIAP and to a lesser extent c-IAP-1, and bcl-X L in all tested HTLV-I-negative cell lines likely explaining the caspase-dependent apoptosis. Effect of PS-341 on HTLV-I transformed and negative T cells R Nasr et al 1994; Nasr et al., 2003) . Hence, proteasome inhibition by PS-341 would be expected to diminish IkB proteolysis in Tax-positive cells. Indeed, in HuT-102, MT2, C8166 and C91-PL cells, Western blot analysis demonstrated that PS-341 treatment resulted in a significant increase in IkB-a, IkB-b and IkB-e protein level in a dose dependent manner (Figure 6a and data not shown). In contrast, the level of IkB-a, IkB-b and IkB-e was either unaffected or even decreased in the four tested HTLV-Inegative cells (Figure 6a and data not shown). We then examined whether, following stabilization of the NF-kB inhibitors, PS-341 treatment could modulate the NF-kB functional assembly by assessing DNA binding NF-kB complexes. We first confirmed the constitutive expression of NF-kB in the HTLV-Ipositive cells HuT-102, MT2, C8166 and C91-PL cells by EMSA. One predominant positive complex was detected by the 32 P-labeled NF-kB consensus oligonucleotide ( Figure 6b and data not shown). This complex disappeared in the presence of excess of unlabeled NFkB consensus oligonucleotide, but not with excess unlabeled mutant oligonucleotide (Figure 6b ), confirming its specificity. PS-341 exposure resulted in a dosedependent inhibition of NF-kB complex formation in MT-2 cells where the NF-kB complex was slightly reduced upon exposure to 3 nM PS-341 and drastically reduced by exposure to 5-10 nM PS-341 (Figure 6b ). In HuT-102 and C91-PL cells, PS-341 resulted in a drastic reduction of the NF-kB complexes at 10 nM only (Figure 6b and data not shown). As expected, in HTLV-I-negative cells (CEM, Jurkat and MolT-4), gel shift assays using NF-kB consensus oligonucleotide showed a faint band complex reflecting the absence of constitutive NF-kB activation.
PS-341 treatment stabilized
The specificity of these NF-kB complexes was further confirmed using RelA and p50 specific antibodies to induce a super-shift. As previously reported (El-Sabban et al., 2000) , in HTLV-I-positive cells, RelA and p50 lead to super-shifting of a fraction of the NF-kB complexes (Figure 6c and data not shown). In all tested HTLV-I-positive cells (HuT-102, MT-2 and C91-PL), RelA containing complexes were drastically reduced upon exposure to 5-10 nM PS-341 (Figure 6c and data not shown) while p50 containing complexes were slightly reduced in HuT-102 cells and remained unaffected in C91-PL cells (data not shown). This dramatic and specific decrease in RelA containing complexes is consistent with enhanced expression of IkB-a, IkB-b and IkB-e, which sequester RelA to the cytoplasm. Indeed, using anti-RelA antibodies, a mixed homogeneous nuclear and cytoplasmic staining was observed in the majority of untreated MT-2 cells, while cells treated with PS-341 showed exclusively cytoplasmic staining (Figure 6d ).
PS-341 inhibited Tax degradation and upregulated p53, p21 and p27 proteins in ATL-derived cells
We have previously reported a significant stabilization of Tax in HTLV-I infected cells treated with the proteasome inhibitor zLLL (Nasr et al., 2003) . Similar results were observed with PS-341. Treatment of HuT-102, MT-2 and C91PL cells with 5-10 nM PS-341 resulted in a significant upregulation of Tax protein level (Figure 5c and data not shown). These results confirm our previous report of a continuous proteasome-mediated degradation of Tax in HTLV-I-positive cells. On the other hand, treatment of these cells with 3-10 nM PS-341 resulted in a significant increase in p21, p27 and p53 protein level in a dose-dependent manner, indicating an inhibition of their baseline proteasomal degradation (Figure 5b ). In contrast, in the HTLV-I-negative cells CEM, Molt-4 and Jurkat, PS-341 treatment slightly upregulated p53 while p21 and p27 protein levels were unaffected. These results suggest a potential involvement of the p53 pathway in PS-341-induced growth inhibition of HTLV-I-positive cells.
PS-341 induced ceramide accumulation in malignant T cells
Ceramide, a coordinator of the cellular response to stress (Hannun, 1996) , has several growth suppressive effects including cell cycle arrest (Dbaibo et al., 1995) and apoptosis (Obeid et al., 1993) . In both HTLV-Ipositive and -negative cells, PS-341 treatment resulted in Effect of PS-341 on HTLV-I transformed and negative T cells R Nasr et al dramatic ceramide accumulation in a dose-and timedependent manner that correlated with the induction of cell death, potentially implicating the ceramide pathway in PS-341-induced growth arrest and apoptosis. PS-341 treatment of MT-2 cells increased intracellular ceramide to 4.5-fold at 48 h with 10 nM PS-341 (Po0.01) (Figure 5d ), while HuT-102 cells, which are less sensitive to PS-341, showed a lower increase in ceramide. HTLV-I-negative cells displayed a similar correlation between sensitivity to PS-341 and ceramide accumulation reaching eight-fold at 24 h for CEM cells and seven-fold at 48 h for Jurkat cells treated with 10 nM PS-341 (Po0.01) (Figure 5d ).
PS-341 has an additive growth inhibition with doxorubicin and etoposide in ATL-derived and HTLV-I-negative malignant T cells NF-kB activation protects tumor cells from chemotherapy-induced apoptosis (Baeurle and Baltimore, 1996; Huang et al., 2000) . Therefore, PS-341-induced reversal of NF-kB activation could restore the chemosensitivity of ATL-derived cells. We investigated the effect of PS-341 in combination with doxorubicin and etoposide. After 24 h treatment, the growth of Molt-4 cells was reduced to 62% of control with 3 nM PS-341, 20% with 1 mM etoposide, 50% with 100 nM doxorubicin, 10% with the combination PS-341 and etoposide and 20% with the combination 
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of PS-341 and doxorubicin (Po0.01) (Figure 7 ). CEM cells showed a similar additive effect of the combination of PS-341 and doxorubicin (Po0.05) but not etoposide ( Figure 7) . In HTLV-I-positive cells, after 48 h treatment, the growth of HuT-102 cells was reduced to 54% of control with 5 nM PS-341, 46% with 1 mM etoposide, 62% with 100 nM doxorubicin, 34% with the combination PS-341 and etoposide, and 31% with the combination of PS-341 and doxorubicin (Po0.05) (Figure 7 ). These results indicate that the combination of PS-341 and doxorubicin resulted in an additive rather than synergistic effect in CEM, Molt-4 and HuT-102 cells, while the combination of PS-341 and etoposide resulted in an additive effect mostly in Molt-4 cells. The additive effect of these combinations was lost when lower doses of PS-341 and/or chemotherapy were used (data not shown). Interestingly, MT-2 cells in which growth and NF-kB activity are more inhibited by PS-341 compared to other HTLV-I-positive cells, displayed a modest additive effect of PS-341 with etoposide and doxorubicin, suggesting that the constitutive activation of the NF-kB pathway in HTLV-I-positive cells plays a little role in their resistance to chemotherapeutic agents.
Discussion
We show that clinically achievable concentrations of PS-341 induce growth inhibition, cell cycle arrest and Ceramide levels were determined after 24 and 48 h using the DGK assay as described in 'Materials and methods' and normalized to total cellular inorganic phosphate levels. Results are expressed as fold increase in total ceramide levels7s.d.
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apoptosis in all tested malignant T cells, while no effect was observed on resting and activated normal Tlymphocytes. The mechanism for this differential sensitivity of transformed cells to PS-341, which has been reported in other cell types, remains to be elucidated. In HTLV-I-negative malignant T cells, PS-341 treatment significantly downregulated the antiapoptotic protein X-IAP and to a lesser extent c-IAP-1, and bcl-XL, induced ceramide accumulation and resulted in a significant loss of mitochondrial membrane potential and caspase activation. Importantly, PS-341-induced growth inhibition was partially but significantly reversed by caspase inhibitors, which inhibit cell cycle progression in T and B lymphocytes (Alam et al., 1999; Olson et al., 2003) . Hence, the protective effect of zVAD in PS-341-treated HTLV-I-negative cells demonstrate the involvement of caspase activation and caspase-dependent apoptosis in PS-341-induced growth inhibition of HTLV-I-negative cells.
In contrast, a different mechanism of action of PS-341 was observed in HTLV-I infected cells. In agreement with recent reports (Tan and Waldmann, 2002; MitraKaushik et al., 2004; Satou et al., 2004) , we show that in HTLV-I transformed cells, PS-341 treatment resulted in a dramatic stabilization of IkB-a, IkB-b and IkB-e proteins and reversal of NF-kB activation with a more selective inhibition of Rel-A DNA binding NF-kB complexes. Previous studies clearly established the importance of NF-kB activation and RelA containing complexes in both HTLV-I induced transformation and resistance to apoptosis (Kitajima et al., 1992; Yamaoka et al., 1996) .
Although RelA appears to be a major target of PS-341, the effects of this proteasome inhibitor on HTLV-Ipositive cells were not limited to the inhibition of the NF-kB pathway. PS-341 treatment resulted in a dramatic stabilization of p21, p27 and p53 proteins in a dose-dependent manner. In HTLV-infected cells, p53 is sometimes mutated but most frequently functionally inactive (Cereseto et al., 1996; Mahieux et al., 2000) and Tax-dependent activation of the NF-kB pathway was reported to play a critical role in the inhibition of p53 transactivation function . Hence, PS-341-induced p53 accumulation, together with the reversal of NF-kB activation, should restore normal p53 function. The upregulation of p21 and the delayed upregulation of bax, two well characterized p53 targets, argue in favor of this hypothesis. Interestingly, PS-341 effects on p21 and p27 proteins were limited to HTLV-Ipositive cells, whereas no significant change was seen in HTLV-negative malignant T cells. Tax has been reported to transactivate the p21 promoter and, consequently, p21 expression is upregulated at both the transcript and protein levels in HTLV-I infected cells (Cereseto et al., 1996; De La Fuente et al., 2000) . However, p21 effects on preventing apoptosis and stimulating growth of HTLV-I-positive cells (Kawata et al., 2003) are described in a cellular environment, where NF-kB is constitutively activated and p53 transcriptional activity is inhibited. In the absence of NF-kB activity and in the presence of active p53, PS-341-induced accumulation of p21 and p27 should result in cell cycle arrest rather than growth promotion and protection from apoptosis.
As for HTLV-I-negative cells, PS-341 treatment of HTLV-I infected cells resulted in ceramide accumulation and loss of mitochondrial membrane potential, which may explain caspase activation. However, activation of caspase was only partial and importantly, PS-341-induced growth inhibition of HTLV-I-positive cells was not reversed by zVAD, except partially for MT-2 cells. That HTLV-I-negative cells are more sensitive than their HTLV-I-positive counterpart to PS-341 effects is in agreement with previous reports that Tax protects HTLV-I-positive cells from caspase-dependent apoptosis (Kawakami et al., 1999) through upregulation of NF-kB-dependent apoptosis inhibitors such as bcl-X L or caspase inhibitors such as c-IAP-1 and XIAP. However, despite complete reversal of NF-kB activation, PS-341 treatment had no detectable effect on XIAP and bclX L proteins levels in ATL-derived cells, contrary to HTLV-I-negative cells. These results, together with the inhibition of the proteasomal degradation of Tax by PS-341, suggest that Tax protects HTLV-I infected cells against caspase-dependent apoptosis through an NF-kB independent upregulation of XIAP. The mechanism underlying downregulation of XIAP protein levels in PS-341-treated HTLV-I-negative cells remains to be elucidated.
Although Tax is undetectable in circulating ATL cells, our demonstration that Tax is continuously degraded by the proteasome may account for the subsequent presentation of Tax peptides on MHC class I molecules (Lomas et al., 2002) and for the high frequency of circulating Tax-specific cytotoxic T lymphocytes found in most HTLV-I-infected individuals (reviewed in Bangham, 2000) . ATL cells may display a latent, transient and/or low level of Tax expression in preferential sites involved by tumor cells such as skin, gastrointestinal tract and/or other lymphoid organs.
Since Tax is an essential activator of the viral gene expression, which is absolutely indispensable to replication, PS-341 treatment may be clinically useful not only in ATL but also in patients with tropical spastic paraparesis/HTLV-I associated myelopathy, in chronic HTLV-I carriers with high viral loads or during primoinfection.
Combination of PS-341 and the chemotherapeutic agents doxorubicin or etoposide resulted in an additive inhibition of cell growth in most tested cells. Conventional chemotherapy has limited benefit in ATL patients given that HTLV-1 cells carry an intrinsic resistance to chemotherapy due to frequent overexpression of the multidrug resistance protein (Lau et al., 1998) and the lung resistance protein (Ikeda et al., 1999) . In addition, the constitutive activation of NF-kB, the inhibition of p53 function and the downregulation of Fas-ligand expression in HTLV-I-positive cells (Tamiya et al., 1998) likely protect these cells from chemotherapy-induced apoptosis. Hence, the reversal of NF-kB activation by PS-341 and the potential restoration of p53 function should enhance the chemosensitivity of HTLV-I-positive cells resulting in a synergistic inhibition of cell growth. In that sense, in murine models of ATL, PS-341 synergized with humanized anti-Tac monoclonal antibodies (Tan and Waldmann, 2002) or with g-irradiation (Mitra-Kaushik et al., 2004) while single agents had little effect. However, our results showed that combination of PS-341 with doxorubicin and etoposide resulted in additive effect in most tested ATL-derived and HTLV-I-negative malignant T cells but no real synergy was noted. Some tested cell lines did not even show an additional growth inhibition with the combined therapy. This suggests that PS-341 and tested chemotherapeutic agents have distinct cellular targets and that activation of NF-kB and inhibition of p53 function play a marginal role in the chemo-resistance of ATL cells.
ATL remains of poor prognosis. Novel effective drugs are warranted to reduce the emergence of resistant clones. In addition, HTLV-I-negative peripheral T-cell lymphomas are also associated with poor prognosis due to a lower response rate to anthracyclin-based combination chemotherapy and a higher relapse rate as compared to B-cell lymphomas (Gisselbrecht et al., 1998) . Our results demonstrate that PS-341 affects multiple cellular pathways critical for the survival of both HTLV-I-positive and -negative malignant T cells resulting in growth arrest and apoptosis at clinically achievable concentrations. Hence, these findings support a potential therapeutic role for PS-341 in both ATL and HTLV-I-negative T-cell lymphomas, either alone or in combination with chemotherapy.
Materials and methods
Cells, drugs and antibodies
The HTLV-I-infected CD4 þ T cell lines HuT-102, MT-2, C91PL and C8166, and the HTLV-I-negative CD4
þ T cell 
Growth and cytotoxicity assays
Cell growth was assessed by cell count using trypan blue dye exclusion protocols and the CellTiter 96 s cell proliferation assay kit (Promega Corp., Madison, WI, USA). Results are expressed as cell growth relative to untreated controls and are derived from the mean of quadruplicate wells. Results are representative of at least three independent experiments.
TUNEL assay
The terminal deoxytransferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) assay (Boehringer, Mannheim, Germany) was used. Approximately 10 000 cells per sample were acquired and analysed using flow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA) or fluorescent microscopy. Results were analysed using the CellQuest software. Results are representative of two independent experiments.
Measurement of mitochondrial membrane potential
Quantification of mitochondrial membrane potential was determined by rhodamine (R123) (Sigma) retention. PS-341-treated cells were loaded with 5 mM R123 for 30 min at 371C, washed twice and assessed using flow cytometry. Results are representative of two independent experiments.
Cell cycle analysis
PS-341 treated cells were washed twice with cold PBS, fixed in ice cold 100% ethanol, and stored for 24 h at 41C. Subsequently, cells were rinsed with PBS, incubated for 1 h in Tris-HCl buffer (pH 7.4) containing 50 U RNase A and then stained with propidium iodide (PI) (50 mg/ml) (Sigma). Cell cycle analysis was performed using a flow cytometer. Each sample was collected as 10 000 ungated events and analysed using Cell-Quest software. Results are representative of two independent experiments.
Immunoblot analysis
Total cellular proteins were electrophoresed, and transferred onto nitrocellulose membranes (Bio-Rad Laboratories). The blots were blocked for 1 h at room temperature in 5% skimmed milk in TBS (50 mM Tris-HCl and 150 mM NaCl) and probed overnight with primary antibody at 41C. Antibody binding to specific proteins was visualized by enhanced chemiluminescence using the ECL system (Amersham, Buchinghamshire, UK).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described (El-Sabban et al., 2000) . Protein concentration was determined using the Biorad assay (Bio-Rad Laboratories, Hercules, CA, USA). NF-kB consensus oligonucleotide (Santa Cruz, CA, USA) was endlabeled with g-32 P ATP using T4 polynucleotide kinase. Hybridization reaction was performed as described (El-Sabban et al., 2000) . The reaction mixture was electrophoresed on a 5% nondenaturing polyacrylamide gel, dried at 801C under vacuum for 2 h on Whattman filter paper, and processed for autoradiography. Specific NF-kB bands were determined by competition experiments using a mutant oligonucleotide that has lost its ability to bind to the transcription factor. Subunit specificity was determined by using specific antibodies to the NF-kB components (anti-RelA, p50, c-Rel and p52) in the incubation step, known to super-shift NF-kB complexes.
Immunofluorescence
Cells were fixed in 70% ice-cold ethanol and processed for indirect immunofluorescence. Samples were blocked by incubation with normal goat serum (10% in PBS), reacted with anti-RelA antibodies for 2 h at room temperature, washed in PBS and incubated with FITC-conjugated secondary antibodies. Nuclear translocation of RelA was assessed by fluorescence microscopy (LSM 410, Zeiss, Germany).
Ceramide measurement
Ceramide was measured with a modified diacylglycerol kinase assay using external ceramide standards as described (Bligh and Dyer, 1959; Bielawska et al., 2001) . Briefly, dried lipid was solubilized in (7.5% octyl-b-D-glucoside, 25 mM dioleoyl phosphatidylglycerol) solution. To the lipid micelles, reaction buffer was added, and the reaction was started by adding [g-32 P]ATP solution and allowed to proceed at 251C for 30 min. Lipid extracts were resuspended in methanol/chloroform (1 : 9, v/v) and spotted on silica gel thin layer chromatography plate. Plates were developed with chloroform : acetone : methanol : acetic acid : H 2 O (50 : 20 : 15 : 10 : 5), air dried, and subjected to autoradiography. The radioactive spots corresponding to phosphatidic acid and ceramidephosphate, the phosphorylated products of diacylglycerol and ceramide, respectively, were identified by comparison to known standards, scraped and counted on a scintillation counter.
Statistical analysis
Four statistical tests were performed: The Fisher test, the Dunnett test, the two-way analysis of variance (ANOVA) test, and the two-sample t-test as described (Zar, 1999) .
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